Since the outbreak of COVID19, Pandorum is expanding its reach by further developing the exosome platform, particularly for the post COVID19 trauma. Exosome therapy is a cell-free therapy and with the manifestation of the defined set of cargo, healing of lung tissue in the COVID19 patients could be made easier. In this therapy, exosomes packed with immuno-modulatory, anti-fibrotic factors could alleviate the pain, inflammation, and pulmonary fibrosis which will lead to the tissue repair. Unlike the conventional therapeutic strategies, their physiochemical stability in the body as well as multidimensional packaging significantly reduces the risk of adverse effects and provides a cell-free regenerative medicine.
Pandorum’s Approach: Generation of therapeutic grade extracellular vesicles (EVs) with specific cargo loaded proteins is the principal objective for the treatment of regenerative therapy. Scalable MSCs expansion with an optimized culture condition to select therapeutically enriched EVs are in progress for the development of proprietary Pandorum technology platform.